Cite
APA Citation
Massard, C., Mateo, J., Loriot, Y., Pezaro, C., Albiges, L., Mehra, N., Varga, A., Bianchini, D., Ryan, C. J., Petrylak, D. P., Attard, G., Shen, L., Fizazi, K., & de Bono, J. (2017). phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Annals of oncology, 28, 90–95. http://access.bl.uk/ark:/81055/vdc_100126094932.0x00002b